Total
|
95.9
|
54.0
|
41.9
|
–
|
–
|
Hospital type
|
General
|
40.0
|
38.7
|
78.6
|
−4.10
|
<0.001
|
Specialized
|
59.9
|
43.3
|
103.2
| | |
Age at diagnosis (years)
|
<45
|
103.5
|
61.7
|
41.7
|
0.76
|
0.516
|
45–54
|
98.3
|
55.6
|
42.7
| | |
55–64
|
95.4
|
53.6
|
41.8
| | |
≥65
|
90.7
|
49.0
|
41.6
| | |
Sex
|
Men
|
98.8
|
55.7
|
43.1
|
1.31
|
0.191
|
Women
|
92.2
|
51.8
|
40.3
| | |
Education
|
Primary school or below
|
95.4
|
53.7
|
41.7
|
1.84
|
0.138
|
Junior high school
|
94.9
|
54.3
|
40.6
| | |
Senior high school
|
95.2
|
52.0
|
43.2
| | |
Undergraduate or higher
|
102.6
|
58.7
|
43.9
| | |
Occupation
|
Farmer
|
101.1
|
58.1
|
43.0
|
4.80
|
<0.001
|
Enterprise or company employee/worker
|
98.8
|
53.7
|
45.1
| | |
Self-employee or unemployee ununemployee
|
78.8
|
45.8
|
33.0
| | |
Retiree
|
93.5
|
52.7
|
40.8
| | |
Public sector employee
|
98.6
|
53.8
|
44.8
| | |
Others
|
96.5
|
52.9
|
43.6
| | |
Healthcare insurance type
|
Urban employee basic medical insurance
|
99.7
|
54.6
|
45.0
|
3.64
|
0.003
|
Urban resident basic medical insurance
|
82.2
|
43.3
|
38.9
| | |
New rural cooperative medical scheme
|
99.3
|
58.8
|
40.4
| | |
Commercial insurance
|
87.0
|
60.4
|
26.5
| | |
Self-paid
|
85.0
|
46.2
|
38.8
| | |
Other
|
127.0
|
65.0
|
62.0
| | |
Previous-year household income (CNY)
|
<20,000
|
98.1
|
56.1
|
42.0
|
1.48
|
0.219
|
20,000–39,999
|
99.3
|
57.3
|
42.0
| | |
40,000–69,999
|
96.7
|
54.5
|
42.2
| | |
≥70,000
|
92.1
|
50.3
|
41.8
| | |
Clinical stage
|
I
|
76.1
|
40.1
|
36.0
|
16.05
|
<0.001
|
II
|
77.4
|
42.8
|
34.6
| | |
III
|
98.0
|
55.6
|
42.4
| | |
IV
|
126.8
|
73.7
|
53.1
| | |
Pathologic type
|
Adenocarcinoma
|
97.0
|
55.0
|
42.0
|
2.25
|
0.026
|
Others
|
82.4
|
46.6
|
35.8
| | |
Therapeutic regimen
|
Surgery
|
70.6
|
39.9
|
30.7
|
18.28
|
<0.001
|
Chemotherapy
|
115.7
|
66.1
|
49.6
| | |
Surgery and postoperative chemotherapy
|
98.2
|
55.8
|
42.5
| | |
Symptomatic treatment
|
93.3
|
49.2
|
44.1
| | |
Concurrent chemoradiotherapy
|
196.2
|
103.0
|
93.2
| | |
Radiotherapy
|
188.0
|
105.1
|
82.9
| | |
Neoadjuvant chemotherapy and surgery
|
91.8
|
53.7
|
38.1
| | |